Verona Pharma plc (VRNA)

Verona Pharma Statistics

Total Valuation

Verona Pharma has a market cap or net worth of $3.18 billion. The enterprise value is $2.97 billion.

Market Cap	3.18B
Enterprise Value	2.97B

Important Dates

The last earnings date was Monday, November 4, 2024, before market open.

Earnings Date	Nov 4, 2024
Ex-Dividend Date	n/a

Share Statistics

Verona Pharma has 81.83 million shares outstanding. The number of shares has increased by 3.55% in one year.

Current Share Class	n/a
Shares Outstanding	81.83M
Shares Change (YoY)	+3.55%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	4.48%
Owned by Institutions (%)	65.31%
Float	49.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	186.85
PB Ratio	24.36
P/TBV Ratio	24.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	527.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.03, with a Debt / Equity ratio of 0.94.

Current Ratio	13.03
Quick Ratio	12.47
Debt / Equity	0.94
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.93

Financial Efficiency

Return on equity (ROE) is -78.03% and return on invested capital (ROIC) is -35.24%.

Return on Equity (ROE)	-78.03%
Return on Assets (ROA)	-28.05%
Return on Capital (ROIC)	-35.24%
Revenue Per Employee	$71,190
Profits Per Employee	-$1.95M
Employee Count	79
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

In the past 12 months, Verona Pharma has paid $1.97 million in taxes.

Income Tax	1.97M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +167.01% in the last 52 weeks. The beta is 0.42, so Verona Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	+167.01%
50-Day Moving Average	33.30
200-Day Moving Average	21.88
Relative Strength Index (RSI)	62.43
Average Volume (20 Days)	1,117,238

Short Selling Information

Short Interest	7.52M
Short Previous Month	7.94M
Short % of Shares Out	9.60%
Short % of Float	n/a
Short Ratio (days to cover)	8.04

Income Statement

In the last 12 months, Verona Pharma had revenue of $5.62 million and -$153.72 million in losses. Loss per share was -$1.93.

Revenue	5.62M
Gross Profit	5.08M
Operating Income	-151.30M
Pretax Income	-123.69M
Net Income	-153.72M
EBITDA	-150.30M
EBIT	-151.30M
Loss Per Share	-$1.93

Balance Sheet

The company has $336.04 million in cash and $122.31 million in debt, giving a net cash position of $213.73 million or $2.61 per share.

Cash & Cash Equivalents	336.04M
Total Debt	122.31M
Net Cash	213.73M
Net Cash Per Share	$2.61
Equity (Book Value)	130.49M
Book Value Per Share	1.59
Working Capital	336.30M

Cash Flow

In the last 12 months, operating cash flow was -$103.77 million and capital expenditures -$45,000, giving a free cash flow of -$103.81 million.

Operating Cash Flow	-103.77M
Capital Expenditures	-45,000
Free Cash Flow	-103.81M
FCF Per Share	-$1.27

Margins

Gross Margin	90.34%
Operating Margin	-2,690.33%
Pretax Margin	-2,698.40%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Verona Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.55%
Shareholder Yield	-3.55%
Earnings Yield	-4.84%
FCF Yield	-3.27%

Analyst Forecast

The average price target for Verona Pharma is $43.83, which is 12.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$43.83
Price Target Difference	12.82%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Verona Pharma has an Altman Z-Score of 1.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.36
Piotroski F-Score	3